Issue Detection and Escalation in Clinical Trial Settings

This webinar on issue detection and escalation in clinical trial settings will review the responsibilities of sponsors, investigators, IRB, vendors and CROs in clinical trial setting to maintain compliance. We will discuss how you can proactively monitor to prevent issues and in case of issue detection, escalate them.

Why Should You Attend:

In recent years the FDA has increased the number of clinical sites and trials that have been inspected and audited.  The number of investigators under investigation or disqualified has increased.  IRBs have been inspected and issued with 483 letters.

What would happen: If the site enrolls some subjects that don't meet all the entry criteria? Have unreported safety issues?  Don't sign the CRF? Are not accurate in reporting the data?  Don't follow their own SOP?  Are these issues hidden in your monitoring reports or not there at all?   The FDA does conduct audits of the sites and will issue 483 letters to either the sites or to sponsors. 

Areas Covered in the Seminar:

• Checking the investigators and IRB qualifications and training.
• Preventive risk mitigation methods including training and monitoring sites.
• Considerations for protocol violations.
• Issuing protocol deviations.
• Communication plans with issue escalations and contingency planning.
• Monitor report templates.
• Process maps for risk mitigations and action items including escalation.

Who will Benefit:

This webinar will provide valuable assistance and procedures for sponsors, clinical site managers, CROs, and clinical trial vendors (central labs, drug supply imaging service companies). The following individuals would benefit from this webinar:

• Clinical operations
• Project managers
• Clinical Research Associates (CRA)
• Clinical Trial Associates (CTA)
• Medical monitors
• Pharmacovigilance specialists
• Site managers
• Principle Investigators